Global Drugs for HIV Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for HIV Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
HIV/AIDS is one of the most serious chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.
Drugs for HIV report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for HIV market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Drugs for HIV industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Drugs for HIV key manufacturers include ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Mylan Pharmaceuticals Inc., Genentech, Inc. and AbbVie Inc., etc. ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp are top 3 players and held % sales share in total in 2022.
Drugs for HIV can be divided into Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors, Combination HIV Medicines and Others, etc. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) is the mainstream product in the market, accounting for % sales share globally in 2022.
Drugs for HIV is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, etc. Hospital Pharmacies provides greatest supports to the Drugs for HIV industry development. In 2022, global % sales of Drugs for HIV went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for HIV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
ViiV Healthcare
Gilead Sciences, Inc
Merck Sharp & Dohme Corp
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Theratechnologies Inc.
Mylan Pharmaceuticals Inc.
Genentech, Inc.
AbbVie Inc.
Segment by Type
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Integrase Inhibitors
Combination HIV Medicines
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for HIV market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for HIV, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for HIV industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for HIV in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for HIV introduction, etc. Drugs for HIV Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs for HIV market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.![](http://localhost/mraccuracy/images/About Report.webp)
Drugs for HIV report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for HIV market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Drugs for HIV industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Drugs for HIV key manufacturers include ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Mylan Pharmaceuticals Inc., Genentech, Inc. and AbbVie Inc., etc. ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp are top 3 players and held % sales share in total in 2022.
Drugs for HIV can be divided into Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors, Combination HIV Medicines and Others, etc. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) is the mainstream product in the market, accounting for % sales share globally in 2022.
Drugs for HIV is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, etc. Hospital Pharmacies provides greatest supports to the Drugs for HIV industry development. In 2022, global % sales of Drugs for HIV went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for HIV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
By Company
ViiV Healthcare
Gilead Sciences, Inc
Merck Sharp & Dohme Corp
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Theratechnologies Inc.
Mylan Pharmaceuticals Inc.
Genentech, Inc.
AbbVie Inc.
Segment by Type
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Integrase Inhibitors
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for HIV market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for HIV, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for HIV industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for HIV in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for HIV introduction, etc. Drugs for HIV Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs for HIV market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
![](http://localhost/mraccuracy/images/About Report.webp)